120 related articles for article (PubMed ID: 22267299)
1. Initiating a glucagon-like peptide-1 receptor agonist in the management of type 2 diabetes mellitus.
Gavin JR
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S16-21. PubMed ID: 22267299
[TBL] [Abstract][Full Text] [Related]
2. Incorporating glucagon-like peptide-1 receptor agonists into clinical practice.
Spellman CW
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S7-15. PubMed ID: 22267302
[TBL] [Abstract][Full Text] [Related]
3. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
Nadeau DA
Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
[TBL] [Abstract][Full Text] [Related]
4. Patient education and monitoring recommendations for the use of glucagon-like peptide-1 receptor agonists.
Haines ST
J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S44-8. PubMed ID: 19744425
[TBL] [Abstract][Full Text] [Related]
5. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman JS
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
[TBL] [Abstract][Full Text] [Related]
6. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
7. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
Mannucci E
G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
[No Abstract] [Full Text] [Related]
8. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes.
Nadeau DA
Postgrad Med; 2010 May; 122(3):7-15. PubMed ID: 20463409
[TBL] [Abstract][Full Text] [Related]
9. Practical applications of therapy with a glucagon-like peptide-1 receptor agonist.
Shomali ME
J Fam Pract; 2009 Sep; 58(9 Suppl Treating):S35-43. PubMed ID: 19744424
[TBL] [Abstract][Full Text] [Related]
10. Advances in the treatment of type 2 diabetes mellitus.
Israili ZH
Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
[TBL] [Abstract][Full Text] [Related]
11. [Glucagon-like peptide-1 receptor agonists].
Kurose T; Seino Y
Nihon Rinsho; 2012 May; 70 Suppl 3():689-92. PubMed ID: 22768599
[No Abstract] [Full Text] [Related]
12. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
Moon HS; Kim MK; Son MH
Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
[TBL] [Abstract][Full Text] [Related]
13. Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach.
Cornell S
J Clin Pharm Ther; 2012 Jun; 37(3):254-9. PubMed ID: 21955063
[TBL] [Abstract][Full Text] [Related]
14. [Innovations in the treatment of type 2 diabetes mellitus: use of incretins].
Dedov II; Shestakova MV; Sukhareva OIu
Ter Arkh; 2010; 82(10):5-10. PubMed ID: 21341455
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes: an expanded view of pathophysiology and therapy.
Unger J; Parkin CG
Postgrad Med; 2010 May; 122(3):145-57. PubMed ID: 20463424
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.
Scheen AJ
Eur J Intern Med; 2012 Mar; 23(2):126-31. PubMed ID: 22284241
[TBL] [Abstract][Full Text] [Related]
17. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
18. Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist.
Campbell RK; Neumiller JJ; White J; Sisson E; Kuhn C
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S2. PubMed ID: 19801362
[No Abstract] [Full Text] [Related]
19. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
20. Common patient concerns about the use of glucagon-like peptide-1 receptor agonists in diabetes mellitus management.
Freeman JS; Gavin JR; Spellman CW
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S22-4. PubMed ID: 22267301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
